Global LAG 3 Inhibitors Trials Intelligence Report Highlights:
- Global LAG 3 Inhibitors Market Dynamics
- Clinical Approaches to Target LAG 3 Inhibitors
- Role of LAG 3 Inhibitors in Cancer, Autoimmune Disorders
- Number of LAG 3 Inhibitors Drug In Trials
- LAG 3 Inhibitors Approved Patent Insight
- LAG 3 Inhibitors Trials By Phase, Company, Country, Indication
- Company Agreement/Partnership/Deals For Ongoing Trials
- Global LAG 3 Inhibitor Market Future Outlook
For Report Sample Contact email@example.com
Lymphocyte activation gene-3 (LAG-3) is a member of immunoglobulin superfamily and CD4 ancestral homolog, resulting from gene duplication event. The immune receptor LAG-3 is expressed on activated CD4+ and CD8+ T-cells, regulatory T cells (Tregs), and natural killer (NK) cells, as well as on B cells and plasmacytoid dendritic cells. Further genomic analyses have revealed that expression of LAG-3 on T-cells is assumed to be marker for aggressive progression in a broad spectrum of different human tumors such as melanoma, lung cancer, colorectal cancer, glioblastoma, and several others. Therefore, researchers believed that targeting LAG-3 can emerge as an alternative approach in cancer treatment.
Since its characterization in cancer cells, the immunoreceptor has gained significant interest from pharmaceutical companies. The extensive research activities in this field has led to introduction of several LAG-3 targeting drugs including Relatlimab, Tebotelimab, IMP321, BI 754111, Sym022, and others. Currently, no LAG-3 inhibitor has entered the market, but a majority of them are present in clinical trials, suggesting that novel LAG-3 inhibitors will flourish the market in coming 3-5 years. Relatlimab developed by Bristol Myer Squibb represents the most advanced LAG-3 inhibitor in pipeline, which is being evaluated in phase-III clinical trials. Recently in 2021, US FDA has granted priority review for the drug in combination with Nivolumab indiated for the management of melanoma. Thus, it is expected that the drug will gain entry into market by 2022.
Apart from cancer, researchers are also expanding the knowledge of LAG-3 inhibitors in targeting other therapeutic conditions including Parkinson, multiple sclerosis, diabetes, inflammatory bowel disease, and other autoimmune disorders. For instance, GlaxosmithKline has developed novel LAG-3 targeting monoclonal antibody, GSK2831781 which is being evaluated in the management of plaque psoriasis and ulcerative colitis. However, majority of these studies are present in preclinical stages which are expected to be translated to clinical stage during the forecast period.
The global LAG-3 inhibitor market is poised to grow during the forthcoming year which can be justified by the large number of ongoing clinical trials. As per our analysis, there are more than 30 ongoing clinical trials which are evaluating around 15 LAG-3 inhibitors as monotherapy or combinational therapy. The combinational therapy is expected to hold a dominant share in the market owing to enhanced efficacy, targetability, and ability to overcome drug resistance. For instance, recent preliminary results demonstrate the safety of combination targeting PD-1, Tim-3, and Lag-3 in gastric cancer.
The rising geriatric population which are at higher risk of developing the disease is the major driving factor to the market. Further, the rates at which conventional cancer therapies are failing and increasing drug resistance with targeted therapy, will further boost the growth of LAG-3 inhibitors market. The overall market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of majority regions is shifting towards novel therapeutic approach the drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years. In addition, technological advancements in field of science have also enabled to fasten the overall drug development process and reduce the associated cost.
US is expected to dominate the market which is mainly attributed to surge in prevalence of cancer and increase in awareness of targeted drugs. In addition, the presence of pharmaceutical giants which have robust pipeline of LAG-3 inhibitors also propels the regional growth. Furthermore, technological advancements in screening procedure for cancer, increased healthcare expenditure, increasing government initiatives, and rising public awareness are also boost the growth of market. Apart from this, China also represents one of the promising markets which are mainly due to ongoing clinical trials, large target population base, and increasing healthcare expenditures.